Therapeutic potential of leukemia-derived dendritic cells: Preclinical and clinical progress

D. F. Claxton, J. McMannis, R. Champlin, A. Choudhury

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Human leukemia-derived dendritic cells show potential as tools for therapy. Leukemic cells of patients with chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), and chronic myelomonocytic leukemia (CMML) will all undergo substantial differentiation toward dendritic cells (DC) and may be used to drive autologous T cells to acquire anti-leukemic cytotoxicity. This article describes the use of these human leukemia-derived dendritic cells for stimulation of allogeneic donor lymphocytes and presents a clinical trial of autologous CML DC-stimulated lymphocytes.

Original languageEnglish (US)
Pages (from-to)147-155
Number of pages9
JournalCritical reviews in immunology
Volume21
Issue number1-3
StatePublished - 2001

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Therapeutic potential of leukemia-derived dendritic cells: Preclinical and clinical progress'. Together they form a unique fingerprint.

Cite this